Stock Events

Stock Events

Verici Dx 

$0.002900
12
+$0.00+0%Tuesday 12:04

Statistics

Day High
2.91
Day Low
2.91
52W High
2.91
52W Low
0.003
Volume
200
Avg. Volume
0
Mkt Cap
4.54M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Sep 14Expected
Q2 2024
Q1 2025
Q1 2025
Q2 2025
Q1 2026
Q2 2026
-0.01
-0
-0
-0
Expected EPS
N/A
Actual EPS
N/A

Financials

-189.22%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.66MRevenue
-6.93MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VRCDF. It's not an investment recommendation.
Alphabet
5
GOOGL
Vanguard S&P 500 UCITS - Dist
5
VUSA.LSE
Rolls-Royce
5
RR.LSE
Apple
4
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap23.99B
Guardant Health, Inc. provides liquid biopsy tests, competing in the broader diagnostic and personalized medicine space alongside Verici Dx.
Natera
NTRA
Mkt Cap59.72B
Fulgent Genetics
FLGT
Mkt Cap567.37M
Fulgent Genetics, Inc. provides comprehensive genetic testing, competing in the genetic diagnostics market alongside Verici Dx.
QuidelOrtho
QDEL
Mkt Cap908.62M
QuidelOrtho Corporation specializes in diagnostic testing solutions, including those for transplant monitoring, competing with Verici Dx's offerings.
Myriad Genetics
MYGN
Mkt Cap607.38M
Myriad Genetics, Inc. provides genetic tests for cancer and other conditions, directly competing in the personalized medicine and diagnostics market.
Pacific Biosciences of California
PACB
Mkt Cap809.71M
Pacific Biosciences of California, Inc. offers sequencing solutions that can be used in diagnostic applications, indirectly competing with Verici Dx.
Illumina
ILMN
Mkt Cap35.63B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, indirectly competing in the diagnostics and research market relevant to Verici Dx.

About

Verici Dx plc is an immuno-diagnostics company primarily focused on the kidney transplantation sector. The firm specializes in creating both predictive and diagnostic assays for patients who have undergone kidney transplants. Its development pipeline features Clarava, a pre-transplant tool designed to forecast the likelihood of early acute rejection; Tuteva, a post-transplant assessment focusing on acute cellular rejection; and Protega, an innovative liquid biopsy aiming to predict the risk of fibrosis and eventual graft failure. Established in 2020, Verici Dx plc maintains its headquarters in Penarth, United Kingdom.
Show More
CEO
Sara jane Barrington
Employees
18
Country
United Kingdom
ISIN
GB00BM8HZD43
WKN
000A2QGXF

Listings

STU
DE
63V.STU
F
DE
63V.F
LSE
GB
VRCI.LSE
OTC Link
US
VRCDF

0 Comments

Share your thoughts

FAQs

What is Verici Dx stock price today?▼
The current price of VRCDF is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Verici Dx stock price performance more closely on the chart.
What is Verici Dx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Verici Dx stocks are traded under the ticker VRCDF.
What is Verici Dx market cap?▼
Today Verici Dx has the market capitalization of 4.54M
When is the next Verici Dx earnings date?▼
Verici Dx is going to release the next earnings report on July 5, 2027.
What is Verici Dx revenue for the last year?▼
Verici Dx revenue for the last year amounts to 3.66M USD.
What is Verici Dx net income for the last year?▼
VRCDF net income for the last year is -6.93M USD.
How many employees does Verici Dx have?▼
As of November 6, 2026, the company has 18 employees.
In which sector is Verici Dx located?▼
Verici Dx operates in the Health & Wellness sector.
When did Verici Dx complete a stock split?▼
Verici Dx has not had any recent stock splits.
Where is Verici Dx headquartered?▼
Verici Dx is headquartered in Cardiff, United Kingdom.